Key points
- HGH Fragment 176-191 is not the full growth hormone; it is a fragment derived from the C-terminal region of the GH molecule.
- AOD-9604 is a modified peptide related to, but not chemically identical to, the HGH fragment.
- Positive results regarding fat oxidation and lipolysis have been reported in preclinical models.
- AOD-9604 advanced to clinical trials in a human obesity development program, but significant superiority over placebo in weight loss at 12 weeks could not be demonstrated in the study with 536 participants.
- The FDA draws attention to issues such as immunogenicity, peptide impurities, API characterization, and limited safety data in compounded AOD-9604 products.
What is HGH Fragment 176-191?
Human growth hormone is a polypeptide with 191 amino acids. Whether sequences in the C-terminal portion of the molecule can affect fat metabolism independently of the growth effects of full GH has long been investigated. The name “HGH Fragment 176-191” is widely used for research peptides derived from this region.
How does it differ from AOD-9604?
AOD-9604 is a modified analog of the sequence corresponding to the 177-191 region of human GH, with an additional tyrosine added to its N-terminus. Therefore, it is not correct to consider the terms AOD-9604 and “HGH Fragment 176-191” completely synonymous. Which molecule is actually present in commercial products must also be verified.
Why was it developed for fat loss?
Preclinical studies reported that AOD-9604 increased fat oxidation and lipolysis in obese animals, reduced weight gain, and could produce metabolic effects without exhibiting some of the glucose/insulin effects of full growth hormone. These results led to the molecule entering clinical development as an obesity drug.
What happened in the human clinical development program?
AOD-9604 was evaluated in early human research, including oral and intravenous routes. According to the FDA’s comprehensive 2024 review, most studies could not demonstrate a significant weight-reducing effect compared with placebo. In an obesity study conducted in Australia with 536 participants, weight loss at the 12-week primary endpoint was also not found to differ significantly from placebo, and the company discontinued its drug development program for obesity.
Does this result mean that the peptide has no biological effect?
No. Preclinical findings on lipolysis and metabolism indicate that the molecule may be biologically active. However, what matters in clinical drug development is whether this biological effect translates into a meaningful, reproducible health outcome of sufficient magnitude in humans. The example of AOD-9604 illustrates well why mechanistic success and clinical efficacy must be evaluated separately.
2026 compounding and safety framework
The FDA’s current compounding safety page identifies risks related to immunogenicity, peptide-related impurities, and characterization of the active pharmaceutical ingredient for AOD-9604 with certain routes of administration. The FDA also states that safety information is limited and that serious adverse events have been reported, but causality is unclear. AOD-9604 is not an FDA-approved obesity drug.
Why does the route of administration matter?
Although oral and IV administration were studied in the early human development of AOD-9604, this does not mean that a standard IV protocol currently exists for wellness or weight management. The FDA’s 2024 evaluation also stated that it had not identified sufficient published information on human use via subcutaneous or transdermal routes. When the route of administration changes, the pharmacokinetic and safety profiles may also change.
Its role in weight management today
Obesity treatment has changed significantly in recent years. In addition to nutrition, physical activity, sleep, behavioral support, and preservation of muscle mass, modern pharmacological options supported by strong randomized trial data are available for suitable patients. Therefore, research peptides such as HGH fragment/AOD-9604 should be evaluated in a research category separate from current standard weight management options. For a detailed approach, you can consult the Weight Management and Metabolic Health guide.
Our approach at our Bodrum clinic
When pursuing fat loss, we do not focus solely on the question, “Does it increase lipolysis?” Body composition, waist circumference, muscle mass, glucose-insulin balance, sleep, nutrition, medications being used, and cardiometabolic risk are evaluated together. When research peptides such as HGH fragment or AOD-9604 come up, the identity of the actual molecule, the product source, the route of administration, and human clinical outcomes are each addressed separately.
Frequently asked questions
Does HGH Fragment 176-191 burn fat?
Positive effects related to fat metabolism have been reported in preclinical models. However, there are no strong data demonstrating sustained and clinically meaningful weight loss in humans.
Are AOD-9604 and HGH Fragment 176-191 the same?
Not exactly. AOD-9604 is a modified analog developed from the C-terminal region of GH and contains an additional N-terminal tyrosine. The names are frequently used interchangeably in online products.
Is IV AOD-9604 standard?
No. The fact that the IV route was studied in early clinical trials does not mean that there is currently an approved or standardized IV weight loss protocol.
Related content
- Weight Management and Metabolic Health
- Obesity and Inability to Lose Weight
- Insulin Resistance and Metabolic Syndrome
- Main Guide to Peptide Applications
- CJC-1295
- Ipamorelin
References
- Ng FM, et al. Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone. Horm Res. 2000. PMID: 11146367.
- U.S. FDA. December 4, 2024 Pharmacy Compounding Advisory Committee: AOD-9604 related bulk drug substances for obesity.
- U.S. FDA. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. Updated 2026.
Written and medically reviewed by: Dr. Kerem Çağlayan
Last medical review: 10 September 2026
Disclaimer: This content is intended for general medical information; it is not a substitute for individual diagnosis or treatment recommendations.
